1. Pink Sheet
  2. >>Market Access

Medicare Premium Hike Will Help Build ‘Contingency Fund’ For Alzheimer’s Drugs

 
• By Cathy Kelly

But CMS cautions that the announcement should not be read as a preview of its upcoming national Medicare coverage decision on Aduhelm and similar treatments.

Big Drug Expenses Ahead For Medicare? • Source: Alamy

The Medicare Part B standard monthly premium will increase $21.60 to $170.10 in 2022, an unprecedented spike in dollar terms, due to factors including the need to set aside reserves to potentially pay for Biogen, Inc.'s and Eisai Co., Ltd.’s high-cost Alzheimer’s drug, Aduhelm, and similar treatments, the Centers for Medicare and Medicaid Services announced 12 November.

Part B premiums will increase 14.5% in 2022, far outstripping earlier estimates. Deductibles will rise by a similar percentage, from...

Welcome to Pink Sheet

Create an account to read this article

Already a subscriber?

More from Market Access

England Prioritizes SGLT-2s & GLP-1s In Diabetes Market Access ‘Shake Up’

 
• By Neena Brizmohun

Recommendations from the health technology assessment institute, NICE, reflect a strategic shift from treating type 2 diabetes to proactively preventing future complications of the condition.

Lilly’s Direct-To-Consumer Portal Implicated In Texas Anti-Kickback Suit

 
• By Cathy Kelly

Complaint names LillyDirect in action targeting the company’s free nurse and reimbursement support programs for health care providers.

‘We Need To Move With The Times’: Cell & Gene Therapy Catapult CEO On UK’s Regulatory Overhaul

 
• By Eliza Slawther

The UK drug regulator has introduced several changes in recent months, such as the introduction of a decentralized manufacturing regulation. Matthew Durdy, CEO of the Cell and Gene Therapy Catapult, explains what these changes mean for the cell and gene industry.

Japan To Cut Leqembi Price By 15% Following Cost Effectiveness Review

 
• By Lisa Takagi

While Japanese government announces 8-15% price cuts for four drugs, including Leqembi, industry groups urge operational improvements to national cost effectiveness assessment scheme.

More from Pink Sheet

‘We Need To Move With The Times’: Cell & Gene Therapy Catapult CEO On UK’s Regulatory Overhaul

 
• By Eliza Slawther

The UK drug regulator has introduced several changes in recent months, such as the introduction of a decentralized manufacturing regulation. Matthew Durdy, CEO of the Cell and Gene Therapy Catapult, explains what these changes mean for the cell and gene industry.

Boosting EU Clinical Trials: EMA Opens Dialogue With Global CRO Group

 
• By Vibha Sharma

The European Medicines Agency’s inaugural bilateral meeting with the Association of Clinical Research Organizations underscores ACRO’s commitment to advancing innovation and its presence in the EU clinical trials ecosystem.

Zimbabwe Tackles Medicines Falsification With New Requirements For Pharma

 
• By Neena Brizmohun

The Medicines Control Authority of Zimbabwe has begun phasing in mandatory package labeling requirements based on GS1 identification standards. It aims to improve the traceability of medicines throughout the entire supply chain.